Inside Putin's multi-billion dollar quest for immortality through biotechnology
By
Miles Bryan, Noel King
Summary
The article explores Vladimir Putin's reported obsession with extending his lifespan through advanced biotechnology, including organ replacement, cryogenics, and genetic research. It references a leaked conversation between Putin and Xi Jinping about living to 150, and details a massive state-funded program in Russia involving mini pigs for organ harvesting, cryo chambers, and billions of dollars in investment. The reporting by Wall Street Journal correspondent Bojan Pancevski uncovers the extent of Putin's personal interest in immortality research and the scientific and ethical implications.
Source
Key quotes
· 3 pulledPutin is quite serious about his issues. So I decided to look up and see what he was talking about. It turned out he was actually referencing a state program.
Last fall, a hot mic caught Vladimir Putin and Xi Jinping gabbing — through a translator — about how organ replacement may soon allow people to live to 150 or older.
Cryo chambers, mini pigs, and $26 billion are fueling his quest for immortality.
You might also wanna read

Putin and Xi Jinping Discuss Organ Transplants and Immortality on Hot Mic
Russian President Vladimir Putin and Chinese President Xi Jinping were accidentally recorded on a hot microphone during a Beijing military p
How the Ultra-Rich Are Pursuing Immortality Through Science and Technology
The article explores how wealthy and powerful individuals — from historical emperors to modern Silicon Valley billionaires — are increasingl
Two New Books Question the Data and Ethics Behind the Quest to Slow Aging
Dhruv Khullar reviews two new books—Saul Justin Newman's "Morbid" and Ezekiel J. Emanuel's "Eat Your Ice Cream"—that critically examine the
The Vampire Theory of Modern Longevity: Why Blood Transfusions Dominate Anti-Aging Research
The article explores the modern longevity movement's obsession with blood transfusions through a satirical vampire lens, suggesting that fig
The value of Chinese Biotech

Goldman Sachs Report Questions Financial Sustainability of Curative Gene Therapies
Goldman Sachs analysts question whether curing patients is a sustainable business model for biotech companies, particularly those developing

Comments
Sign in to join the conversation.
No comments yet. Be the first.